Drugs / Diflomotecan
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00080015 | Mar 2004 → Feb 2005 | small cell lung carcinoma | Ipsen | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Diflomotecan | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00080015 ↗ |
| Known as | BN80915 | “Diflomotecan (BN80915)” NCT00080015 ↗ |
| Action | Inhibit | “DNA topoisomerase I inhibitor” CHEMBL306280 ↗ |
| Modality | Small molecule | — CHEMBL306280 ↗ |
| Route | Intravenous | “administered as a 20-minute IV infusion” NCT00080015 ↗ |
| Target | TOP1 | “DNA topoisomerase I inhibitor” CHEMBL306280 ↗ |